AzTrials
AzTrials

DiarrheaPhase 2/3NCT01166815

Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya.

A Phase 2/3 study testing Zinc sulphate in people with Diarrhea and Malaria, run by United States Army Research Institute of Environmental Medicine at 3 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Zinc deficiency is prevalent in children in developing countries. Zinc-supplementation is proven to reduce the duration and severity of childhood diarrhea in randomized controlled trials. However, despite this evidence, its efficacy to reduce diarrhea morbidity in adults remains unknown. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Diarrhea, Malaria
What is being tested?
Zinc sulphate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
500 participants
Where
3 sitesin 2 countries
Study dates
Jul 2007to Jan 2008
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male or female between 18 and 55 years of age
  • Written informed consent obtained from the volunteer in Dholuo, Kiswahili or English.
  • Available to participate for the study duration (approximately five months)
  • Negative pregnancy test at screening and study start
  • Not taking any vitamin/mineral supplements for the last 2 months prior to onset of the study.

Who cannot join

  • Profound clinical evidence of current immunosuppression or evidence of active AIDS defining illness
  • A family history of congenital or hereditary immunodeficiency
  • History of allergic reactions to zinc
  • History of any neurologic disorders or seizures
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal functional abnormality, as determined by physical examination or laboratory screening tests
  • ALT above normal range: >60 U/L Male; >40 U/L Female
Show all 20Show fewer
  • Creatinine above normal range: >1.5 mg/dL
  • Hemoglobin below normal range: <11.0 g/dL Male; <9.5 g/dL Female
  • Total White Cell Count below normal range <3.0 x 103/uL Male; <2.5 x 103/uL Female
  • Absolute lymphocyte count < 1.0 x 103/uL
  • Platelet count below normal range <100 x 103/uL
  • Pregnant female (positive pregnancy test) at time of screening or study start
  • History of chronic alcohol consumption and/or drug abuse
  • Use of any investigational or non-registered drugs or vaccines within 30 days preceding the first dose of the study, or planned use during the study period
  • Any chronic drug therapy to be continued during the study period
  • Simultaneous participation in any other clinical trial
  • Planning to start or unable to discontinue vitamin/mineral supplements other than those supplied by the study
  • HIV positive with current Aids defining illness or CD4 count less than 250 cells/mm3
  • Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial
  • Persons having diarrhea at the time of enrollment.

Trial locations and contacts

3 sites in 2 countries.

3 sites in 2 countries

United States2 sites
  • U.S. Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Center

    Grand Forks, North Dakota, 56721

  • U.S. Army Research Institute of Environmental Medicine (USARIEM)

    Natick, Massachusetts, 01760

Other trials in United States

Kenya1 site
  • Kombewa Clinical Research Center

    Kombewa, Kisumu West

Other trials in Kenya

About this study

Official title: A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya.

Zinc deficiency is prevalent in children in developing countries. Zinc-supplementation is proven to reduce the duration and severity of childhood diarrhea in randomized controlled trials. However, despite this evidence, its efficacy to reduce diarrhea morbidity in adults remains unknown. The main objective of this study is to determine the efficacy of Zn-supplementation on diarrhea incidences in a vulnerable adult population. The study will be carried out in Kombewa division, Kisumu District and will involve 500 adults aged 18-55 years. They will be randomly assigned to receive Zn supplement (or placebo) on a daily basis over a 3 month period. Morbidity information will be collected daily for 4 months, while anthropometric measures and laboratory data will be obtained at study onset, end of supplementation and study conclusion. In addition, HIV and malaria tests will be carried out during the study as they are important confounders. The significant differences in diarrhea incidence between the Zn-group and the placebo-group will be determined using SPSS. The results are expected to provide the scientific basis and common pathway for development of an anti-diarrheal supplement for vulnerable populations such as environmental refugees, deprived and displaced persons, and troops prior to deployment.

Read the detailed description

Diarrhea has been a major cause of morbidity, hospitalization, and loss of duty days for military personnel for centuries. In fact, diarrheal illness is the most common medical problem for U.S. troops during operational deployment. Soldiers are especially prone to diarrhea because of travel, consumption of locally procured foods (including raw vegetables and poorly-cooked meat products) and the use of nonpotable water, or ice. High rates of occurrence continue to be reported in soldiers deployed to recent conflicts. Furthermore, high morbidity rates from enteric disease have been reported by other military forces in areas of current combat operations: up to 53%-69% of Soviet troops had major gastrointestinal infections during the Afghanistan war, and up to 69% of British troops and 36% of Australian troops reported diarrhea in Iraq during Operation Safe Haven in 1991.

The region of sub-Saharan Africa, where the proposed study would be conducted, is uniquely positioned for anti-diarrheal research that can offer answers to problems of the civilian population, displaced persons and deployed soldiers or workers in remote areas. Diarrheal disease is the 4th leading cause of out-patient morbidity in Kenya, accounting for almost 5% of all new outpatient cases, with a higher prevalence in Nyanza Province - 5.4% to 7.1% of total new cases. Kisumu lies in the Nyanza Province in western Kenya, bordering Lake Victoria and populated by the Luo ethnic group. Nyanza is one of Kenya's most impoverished provinces with one of the nation's lowest immunization rates, highest infant mortality and highest prevalence of HIV (35% among adults 15-49 years old in 2000, as compared to 14% nationally). Malnutrition is common; endemic diseases include malaria, leishmaniasis, tuberculosis and schistosomiasis.

Scientists from the Centers for Disease Control and Prevention (CDC) have reported on the species of bacterial pathogens isolated from diarrhea patients in the Kisumu area: the bacterial isolates were similar to those reported in U.S. soldiers (44% Shigella; 30% Campylobacter; 14% Salmonella). However, most of the isolates (51%) were not susceptible to their antimicrobial treatment. The study by Brooks et al. (2003), reported that more than 90% of the isolates (excluding Campylobacter) were resistant to trimethoprim-sulfamethoxazole and tetracycline, and more than 80% were resistant to ampicillin.

If this alarming trend persists, and drug-resistant bacteria are identified in civilian populations, gains in disease control strategies already deployed will not be achieved, and in case of deployed members of the military or workforce, mission-impact may be severely compromised. Thus, we propose that the Kombewa Clinical Research Center (KCRC), located outside of Kisumu, would allow for testing of a novel anti-diarrheal treatment, specifically dietary zinc (Zn), in antibiotic-resistant bacteria with potential benefits to not only the deployed U.S. military and western Kenyan populations, but also other populations in Africa. Populations living in the Kombewa area will serve as potential study volunteers because of the high prevalence of antibiotic-resistant diarrhea in adults in this region.

This study will build upon the proven concept that Zn-supplementation, as an adjunct to oral rehydration, is highly protective against diarrhea in children. The results are expected to provide the scientific basis and common pathway for development of a commercially viable, multivalent, food-based, anti-diarrheal supplement for vulnerable populations such as troops prior to deployment, deprived and displaced persons. Based on a successful outcome, we would expect to attract commercial support for a final micronutrient formulation suitable for field use and expanded efficacy evaluation in pivotal studies for support of licensure. An anti-diarrheal product for adults will fill an important military, refugee population need and have dual use in the civilian sector.

The benefits of maintaining adequate zinc status in populations in tropical areas and more so displaced populations such refugees and deployed soldiers are probably not limited to the disease states discussed here. Roles for Zn have been described for other important issues facing the soldier and populations in the tropics especially children, including cutaneous leishmaniasis, malaria, pneumonia, wound healing, cognitive function and behavior, and night vision. Because of these important roles for Zn in maintaining health and fighting disease, maintaining adequate Zn levels and supplementing with Zn in some cases, should be considered when formulating diets for resource deprived populations, displaced people and the modern deployed soldiers.

The primary objective of the study is to determine the incidence of diarrhea in zinc vs. placebo-supplemented adults; secondary objectives include: determining the time to diarrhea onset in both groups; determining the duration of each diarrhea episode in both groups; and determining the number of loose stools per day per episode of diarrhea in both groups. Tertiary objectives include determining the nutritional status of the study population by use of anthropometric measurements and micronutrient assays; determining the incidence of malaria in zinc vs. placebo-supplemented adults; and determining if HIV infection is a confounding factor in the outcome of diarrhea incidences following zinc supplementation in adults.

Hypotheses

  1. There is no statistically significant difference in the incidence of diarrhea in adults when given Zn supplementation as compared to placebo over a three month period. We will determine the incidence of diarrhea in both the Zn and placebo arms of the study. This will be accomplished from self-reported incidence of volunteers collected by health workers at the field stations or at the subject's home.
  2. The time to diarrhea onset will not be significantly different in the Zn supplemented study arm as compared to the placebo study arm. We will determine the number of days from the study start (this will be after a two week period of volunteers receiving either Zn supplements or placebo) until onset of diarrhea in both the Zn and placebo arms of the study. This will be accomplished from self-reported data of volunteers collected by health workers at the field stations or at the subject's home.
  3. The duration of each diarrhea episode will not be significantly different in the Zn-supplemented study arm as compared to the placebo study arm. We will determine the number of days of each diarrhea episode in both the Zn and placebo arms of the study. This will be accomplished from self-reported data of volunteers collected by health workers at the field stations or at the subject's home.
  4. The number of loose stools per day per episode of diarrhea will not be significantly different in the Zn-supplemented study arm as compared to the placebo study arm. We will determine the number of number of loose stools per day per episode of diarrhea in both the Zn and placebo arms of the study. This will be accomplished from self-reported data of volunteers collected by health workers at the field stations or at the subject's home.
  5. The incidence of malaria will not be significantly different in Zn vs. placebo-supplemented adults. We will determine the incidence of malaria in both the Zn and placebo arms of the study. This will be accomplished using the results from the malaria blood smears collected during the study.
Conditions
Diarrhea, Malaria
Being tested
Zinc sulphate, Placebo
Keywords
diarrhea morbidity, malaria incidence, zinc supplementation
Medical subject headings
Diarrhea, Malaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Zinc sulphateDietary supplement

    Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.

  • PlaceboOther

    Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.

Study groups in NCT01166815
Study groupRoleWhat they receive
Zinc supplementedActive comparatorVolunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as "A" and "B".
Receives: Dietary Supplement: Zinc sulphate
PlaceboPlacebo comparatorVolunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as "A" and "B".
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine the incidence of diarrhea in zinc vs. placebo-supplemented adults

    Diarrhea is defined as 3 or more loose motions within a period of 24 hours. Field workers will visit each subject to record diarrhea morbidity data, daily for 104 days.

    Measured: Daily, for 104 days

Secondary outcomes (3)
  1. Determine the time to diarrhea onset in both groups

    Daily, field workers will visit each subject to dispense supplement and to record diarrhea morbidity data. The time between day 0 and the first bout of diarrhea will be noted.

    Measured: Daily, for 104 days

  2. Determine the duration of each diarrhea episode in both groups

    Daily, field workers will visit each subject to dispense supplement and to record diarrhea morbidity data. With diarrhea defined as >2 loose motions within a period of 24 hours, the duration (number of days) of the diarrhea will be recorded.

    Measured: Daily, for 104 days

  3. Determine the number of loose stools/day/episode of diarrhea in both groups

    Daily, field workers will visit each subject to record diarrhea morbidity data. With each bout of diarrhea, we will record the nuber of loose stools/day.

    Measured: Daily, for 104 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2010 (estimated)
  2. Study startJul 2007
  3. Primary completionJan 2008
  4. Study completionJan 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
500 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01166815
Sponsor's protocol ID
USARIEM C07-04
Other IDs
WRAIR 1332, KEMRI 1332
Status last verified
Jul 2010
First submitted
19 Jul 2010
Last updated
22 Jul 2010
Results posted
No
Data monitoring committee
Yes

Publications

  • Scrimgeour AG, Lukaski HC. Zinc and diarrheal disease: current status and future perspectives. Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):711-7. doi: 10.1097/MCO.0b013e3283109092.

    PubMed 18827574
  • Scrimgeour AG, Condlin ML. Zinc and micronutrient combinations to combat gastrointestinal inflammation. Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):653-60. doi: 10.1097/MCO.0b013e3283308dd6.

    PubMed 19684516
  • AG Scrimgeour, HC Lukaski, ME Polhemus, L Otieno, SM McGraw, AJ Young, ME Bovill. Effect of Zinc Supplementation on Diarrhea and Malaria Morbidity in Adults in Rural Kenya. FASEB J. 2010 24:538.12

  • AG Scrimgeour, HC Lukaski, ME Polhemus, L Otieno, AJ Young, ME Bovill. Zinc supplementation does not alter plasma trace elements in Kenyan adults FASEB J. 2009 23:922.2.

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Zinc sulphate in people with Diarrhea and Malaria, run by United States Army Research Institute of Environmental Medicine at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jul 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States, Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine the incidence of diarrhea in zinc vs. placebo-supplemented adults (time frame: Daily, for 104 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01166815, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in